Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | TCF4 | P15884 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5763446 | 0.82 | ALDH1A1 (0.48) | MAPTKMT2AALDH1A1 | |
| SCHEMBL5763706 | 0.81 | KMT2A (0.47) | MAPTKMT2AALDH1A1 | |
| SCHEMBL14578755 | 0.81 | KMT2A (0.57) | MAPTKMT2ALMNAALDH1A1 | |
| SCHEMBL397968 | 0.80 | CYP4F2 (0.51) | MAPTKMT2ALMNAALDH1A1 | |
| SCHEMBL5761961 | 0.80 | GAA (0.56) | KMT2AALDH1A1 | |
| SCHEMBL5366521 | 0.79 | PAX8 (0.54) | MAPTKMT2ALMNAALDH1A1 | |
| SCHEMBL10410092 | 0.79 | TDP1 (0.53) | MAPTTDP1LMNA | |
| SCHEMBL24330535 | 0.78 | TDP1 (0.53) | L3MBTL1TDP1LMNA | |
| SCHEMBL14659554 | 0.77 | TDP1 (0.46) | L3MBTL1KMT2ATDP1LMNAALDH1A1 | |
| SCHEMBL6329280 | 0.77 | LMNA (0.55) | MAPTKMT2ATCF4CTNNB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556371-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | WINSTON PHARMACEUTICALS LLC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | GARST MICHAEL (US) | 2005-08-18 | — | — | US | disclosed |
| EP-1556371-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | Winston Pharmaceuticals LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | GARST MICHAEL (US) | 2005-06-30 | — | — | US | disclosed |
| US-6897227-B2 | Prodrugs of proton pump inhibitors | Winston Pharmaceuticals, Inc. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
| WO-2004009583-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | GARST MICHAEL E (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | MAPT 4100/4885L3MBTL1 3178/4885KMT2A 2483/4885 |
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | ABCB11, SLC10A2, SI | MAPT 4128/4885L3MBTL1 4035/4885KMT2A 2592/4885 |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | MAPT 4098/4885L3MBTL1 3350/4885KMT2A 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.